TCGA-33-4589-01A-01R-1443-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 62
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.550
- OXIDATIVE_PHOSPHORYLATION+0.500
- INTERFERON_GAMMA_RESPONSE+0.470
- PANCREAS_BETA_CELLS+0.470
- MYC_TARGETS_V1+0.460
- ALLOGRAFT_REJECTION+0.430
- COAGULATION+0.430
- MTORC1_SIGNALING+0.400
- XENOBIOTIC_METABOLISM+0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.380
Top 10 suppressed
- MITOTIC_SPINDLE-0.400
- WNT_BETA_CATENIN_SIGNALING-0.370
- NOTCH_SIGNALING-0.300
- HEDGEHOG_SIGNALING-0.270
- UV_RESPONSE_DN-0.270
- MYOGENESIS-0.160
- TGF_BETA_SIGNALING-0.150
- ESTROGEN_RESPONSE_EARLY-0.080
- APICAL_JUNCTION-0.040
- UNFOLDED_PROTEIN_RESPONSE+0.020
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AUR-AFUI-TTM1-A-1-0-R-A743-41 | — | C | 0.900 |
| 2 | 551ADCCD-D116-43D8-AABC-E7E111D79E70 | — | — | 0.896 |
| 3 | TCGA-37-3783-01A-01R-1201-07 | — | cohortSQ1 | 0.893 |
| 4 | TCGA-49-4494-01A-01R-1206-07 | — | cohortA1 | 0.876 |
| 5 | SRR33532822 | — | C | 0.875 |
| 6 | TCGA-35-4122-01A-01R-1107-07 | — | cohortA1 | 0.873 |
| 7 | TCGA-05-5425-01A-02R-1628-07 | — | cohortA4 | 0.873 |
| 8 | SRR8518165 | — | C | 0.869 |
| 9 | DB8DD33B-34B6-4F4B-AD87-D666899A26BC | — | — | 0.866 |
| 10 | TCGA-38-4632-01A-01R-1755-07 | — | cohortA1 | 0.861 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.550 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.500 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.470 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.470 | Cobimetinib | — uncovered |
| MYC_TARGETS_V1 | 0.460 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.430 | Idelalisib | — uncovered |
| COAGULATION | 0.430 | Binimetinib | — uncovered |
| MTORC1_SIGNALING | 0.400 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.400 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.380 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.370 | Inavolisib | — uncovered |
| COMPLEMENT | 0.350 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.330 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.320 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.310 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.280 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.270 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.260 | Inavolisib | — uncovered |
| PEROXISOME | 0.230 | Idelalisib | — uncovered |
| HYPOXIA | 0.210 | Idelalisib | — uncovered |